ARS Pharmaceuticals (SPRY) Short term Debt (2020 - 2021)
ARS Pharmaceuticals recorded quarterly Short term Debt of $495000.0 in Q1 2021, down 41.35% quarter-over-quarter from $844000.0 in Q4 2020.
ARS Pharmaceuticals' Short term Debt history runs 2 years deep, the most recent figure standing at $495000.0 for Q1 2021.
- In Q1 2021, Short term Debt changed N/A year-over-year to $495000.0; the TTM figure through Mar 2021 stood at $495000.0 (changed N/A YoY), while the FY2020 annual figure was $844000.0, changed N/A from the prior year.
- Short term Debt came in at $495000.0 for Q1 2021 at ARS Pharmaceuticals, down from $844000.0 in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $844000.0 in Q4 2020 to a low of $495000.0 in Q1 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | ARS Pharmaceuticals | 900.62 Mn | 699.65 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 495,000.00 |
| Dec 31, 2020 | 844,000.00 |